Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
88.6M
-
Number of holders
-
177
-
Total 13F shares, excl. options
-
82.7M
-
Shares change
-
-5.28M
-
Total reported value, excl. options
-
$1.16B
-
Value change
-
-$77.9M
-
Put/Call ratio
-
1.16
-
Number of buys
-
88
-
Number of sells
-
-82
-
Price
-
$13.99
Significant Holders of Travere Therapeutics, Inc. - Common Stock (TVTX) as of Q3 2024
211 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock as of Q3 2024.
Travere Therapeutics, Inc. - Common Stock (TVTX) has 177 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.7M shares
of 88.6M outstanding shares and own 93.31% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (7.65M shares), BlackRock, Inc. (7.56M shares), VANGUARD GROUP INC (6.9M shares), Rock Springs Capital Management LP (4.68M shares), Woodline Partners LP (4.34M shares), MACQUARIE GROUP LTD (4.27M shares), STATE STREET CORP (2.74M shares), EMERALD ADVISERS, LLC (1.96M shares), RENAISSANCE TECHNOLOGIES LLC (1.88M shares), and D. E. Shaw & Co., Inc. (1.84M shares).
This table shows the top 177 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.